<DOC>
	<DOC>NCT02522780</DOC>
	<brief_summary>The purpose of this trial is to investigate the safety and efficacy of mesalamine 2 g extended release granules (sachet) once a day (QD) for maintenance of clinical and endoscopic remission in subjects with UC. The duration of treatment for each subject will be 6 months.</brief_summary>
	<brief_title>Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Male or female subjects aged 18 to 75 years, with Ulcerative Colitis in remission Evidence of other forms of inflammatory bowel disease Infectious disease (including human immunodeficiency virus [HIV], hepatitis B virus [HBV], or hepatitis C virus [HCV]) Disease limited to proctitis &lt;15 cm Short bowel syndrome Prior colon resection surgery History of severe/fulminant UC Intolerant or allergic to aspirin or salicylate derivatives Use of rectal formulations (5aminosalicylic acid [5ASA], steroids) within â‰¤7 days Women who are pregnant or nursing History of known malignancy History of bleeding disorders, active gastric or active duodenal ulcers, autoimmune diseases, or mental/ emotional disorders, that would interfere with their participation in the trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>